SRPT - Sarepta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
120.84
+2.59 (+2.19%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close118.25
Open119.31
Bid120.03 x 1400
Ask122.64 x 800
Day's Range118.23 - 121.22
52 Week Range90.00 - 176.50
Volume605,882
Avg. Volume1,280,661
Market Cap8.961B
Beta (3Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-5.93
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est205.85
  • Market Weekly Review: Lower Prices Create Buying Opportunities
    TipRanks14 hours ago

    Market Weekly Review: Lower Prices Create Buying Opportunities

    Despite gains for U.S. stocks on Friday, the Dow Jones Industrial Average ended lower for a fifth straight week—which is the longest streak since 2011.After a white-hot start to 2019, it’s been a wild wide for investors in the month of May. As the war of words has progressed in the trade battle between China and the U.S., price volatility has been on the increase. Use Volatility to Your AdvantageInvestors tend to shy away from volatility, which is a word that generally is only mentioned when prices are moving lower. In fact, the CBOE Volatility Index (VIX) is often referred to as the “fear gauge.”However, seasoned investors realize that volatility can be your friend. By taking a contrarian stance and buying when prices are lower, you have an opportunity to enter positions at optimal prices and boost long-term performance.“When you put it all together, this is a healthy time to come into the market for the long term,” said Thorne Perkin, president of Papamarkou Wellner Asset Management told CNBC on May 16. “We always look at these pullbacks as buying opportunities for the long term.” Short Holiday WeekThe U.S. markets will be closed next Monday for the Memorial Day holiday. In a short week, Costco (COST), Dell (DELL) and Gap (GPS) are all scheduled to report quarterly results next Thursday. On the economic front, we’ll also get a revision to the reading of first-quarter GDP growth next Thursday. The initial reading last month printed a solid 3.2%. As Memorial Day signals the unofficial start of Summer, look for trading volume to be relatively low next week. With a lot of professional investors at the beach, savvy market watchers will look to take advantage of the increased volatility that can accompany light trading volume. I know that’s the tack I will be taking with the Smart Investor portfolio next week and into the summer. Rather than shy away from any continued volatility, I’ll look to make more purchases, if the market continues to create buying opportunities.The fact remains that attractive investments are out there, if you’re willing to dig a little deeper.One such consumer name that’s worth a closer look is our Stock of the Week below… Stock of the Week: Sarepta Therapeutics (SRPT)Sarepta is a biopharmaceutical firm that’s in the business of treating rare neuromuscular diseases. The company currently has a treatment on the market for Duchenne muscular dystrophy (DMD), Exondys 51; but Sarepta is no one-trick pony. Management filed for approval of a second DMD treatment, golodirsen, in February.We recently added SRPT to our Smart Investor portfolio and are pleased to see that shares were flat compared with another down week for the broader markets. The stock has also gained 3% in the month of May, while the S&P 500 has lost nearly 4%.Looking ahead, these gains should keep on coming. Here’s why:DMD is a rare, but deadly genetic disease. The U.S. Food and Drug Administration has granted Sarepta priority review status to golodirsen and will receive an approval decision by Aug. 19, because of its potential impact. The company is not the only entrant in the DMD market, but management believes that it has at least a one-year head start on Pfizer’s (PFE) attempt to enter the arena. In total, Sarepta has a robust clinical pipeline with over 20 therapies, in various stages of research and development. Earlier this month, the company posted quarterly results that exceeded expectations. Sarepta lost $0.75 a share in the first quarter, while revenue increased 35% from the previous year, to $87 million.Yes, the company is losing money and consensus analyst estimates do not expect sustainable profitability until 2021. However, if Sarepta continues to deliver success in the clinical pipeline that day could come sooner and bring a considerably higher stock price along with it. Analysts See Higher Prices AheadIn the meantime, the analyst community is upbeat about the company’s future. 18 of 19 active analysts rate the stock a Buy (with 1 Hold) and the average price target of $202.13 suggests 67% upside potential.View SRPT Price Target & Analyst Ratings DetailAnalyst Alethia Young of Cantor Fitzgerald sums up the biopharma’s outlook here: “For Sarepta, the focus remains on continued pipeline advancement and growing gene therapy manufacturing capabilities. We continue to see many transformative updates for the company over the coming months, including a potential golodirsen approval on 8/19, potential casimersen approval in 1Q2020, and PPMO data around YE19/1Q20. Key trial initiations include commercial microdystrophin by YE19 and Charcot-Marie-Tooth in 2019.”Moreover, she adds: “We see significant revenue growth ahead with launches and also think the pipeline remains undervalued.” As a result, this top-ranked analyst reiterated her Buy rating with a bullish $231 price target on May 9. From current levels that suggests shares can surge 91%.Finally, I’m encouraged to note the stock sports a Smart Score of 10/10 on TipRanks, underlining the potential for continued price momentum. This new proprietary metric utilizes Big Data to rank stocks based on 8 key factors that have historically been a precursor of future outperformance. View SRPT Smart Score DetailIn addition to the catalysts mentioned above, Smart Score notes that Sarepta has positive sentiment from both hedge funds and investment bloggers.Looking for more top-rated stocks? Check out Analysts' Top Stocks here...

  • Thomson Reuters StreetEvents12 days ago

    Edited Transcript of SRPT earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Sarepta Therapeutics Inc Earnings Call

  • This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note
    Investor's Business Daily12 days ago

    This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note

    An analyst suggested investors look at Sarepta Therapeutics' array of gene therapies on Tuesday after rival Solid Biosciences reported its key gene therapy caused side effects in a patient.

  • Sarepta Therapeutics (SRPT) Q1 2019 Earnings Call Transcript
    Motley Fool17 days ago

    Sarepta Therapeutics (SRPT) Q1 2019 Earnings Call Transcript

    SRPT earnings call for the period ending March 31, 2019.

  • Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up
    Zacks17 days ago

    Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up

    Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.

  • When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?
    Simply Wall St.17 days ago

    When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
    Zacks18 days ago

    Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

    Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 47.81% and 0.11%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press18 days ago

    Sarepta Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.07. The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment ...

  • GlobeNewswire18 days ago

    Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments

    CAMBRIDGE, Mass., May 08, 2019 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the.

  • ACCESSWIRE18 days ago

    Sarepta Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM ...

  • GlobeNewswire18 days ago

    Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy

    Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced it has recently signed an agreement with the Research Institute at Nationwide Children’s Hospital (Nationwide Children’s) giving Sarepta the exclusive option to a Nationwide Children’s gene therapy candidate, calpain 3 (CAPN-3), to treat Limb-girdle muscular dystrophy type 2A (LGMD2A). LGMDs represent a group of distinct genetic neuromuscular diseases with a generally common set of symptoms, including progressive, debilitating weakness and wasting that begins in muscles around the hips and shoulders before progressing to muscles in the arms and legs.

  • Markit19 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Sarepta Therapeutics Inc NASDAQ/NGS:SRPTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.24 billion over the last one-month into ETFs that hold SRPT are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks
    GuruFocus.com24 days ago

    Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks

    Fund releases 1st-quarter portfolio

  • GlobeNewswire25 days ago

    Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019

    Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2019 financial results after the Nasdaq Global Market closes on Wednesday, May 8, 2019. The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. Please specify to the operator that you would like to join the "Sarepta First Quarter 2019 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days.

  • GlobeNewswire26 days ago

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2019, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to thirty-five individuals hired by Sarepta in April 2019. The employees received, in the aggregate, options to purchase 55,035 shares of Sarepta's common stock, and in the aggregate, 28,145 restricted stock units (“RSUs”). The options have an exercise price of $ 116.94 per share, which is equal to the closing price of Sarepta's common stock on April 30, 2019 (the “Grant Date”).

  • 5 Biotech Stocks for a Long-Lived Portfolio
    InvestorPlace26 days ago

    5 Biotech Stocks for a Long-Lived Portfolio

    While the biotech sector saw early gains in 2019, the selling pressure has picked up steam recently as the government continued its scrutiny over the Medicare system and the pricing model for drugs. Not only are biotechnology stocks lower, but so are drug stores and drug plan suppliers. But this could be creating an interesting entry poinnt. Investors could invest in all of those sectors but the biotechnology stocks could prove the most rewarding.Biotechnology companies spend enormous amounts of money and time developing drugs. They will eventually prove to the government that rising product prices are a necessity in developing novel and better drugs. Should they succeed and a drug comes to market, everyone wins. * 7 Stocks to Buy That Ought to Buy Back Shares Patients who need the drug will have another treatment option. Drug plan providers may negotiate better prices and offerInvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech Stocks to Buy: Regeneron Pharmaceuticals (REGN)Source: Shutterstock Regeneron Pharmaceuticals (NASDAQ:REGN) fell 14% on news that its competitor, Novartis AG (NYSE:NVS), secured a speedy review for brolucizumab for use in wet, age-related macular degeneration. In August 2018, the FDA approved Regeneron's marketing for Eylea. But if Novartis has a superior product, this could put pressure on one of Regeneron's major product lines.In 2018, Eylea sales topped $4.1 billion, up from $3.7 billion in 2017.Markets chose to ignore the ongoing success of Regeneron's Dupixent drug. In 2018, sales topped $922 million. The high efficacy and safety profile of the injectable drug will surely drive sales higher this year and beyond. Dermira (NASDAQ:DERM) may have announced good Phase 2b study results last month but the company is a long way away from releasing a competitive product. Sarepta Therapeutics (SRPT)Source: Shutterstock Sarepta Therapeutics (NASDAQ:SRPT) lost about one-third of its value from 52-week highs. Markets are still unhappy over the company's $350 million share offering announced in March. The company said that it would use the proceeds "for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities, including the potential licensing or acquisition of complementary products, technologies and entities."More recently, Sarepta presented a positive development in its gene therapy. With four patients involved in the age group of 4-7, the study met the primary end-point for safety. Secondary endpoints included a decrease in CK and a change in micro-dystrophin expression before and after treatment.In the fourth quarter, Sarepta reported revenue increasing 47.3% Y/Y to $84.4 million. Still, even though the company reported a loss of $2.05 a share (GAAP), EXONDYS 51 revenue for the year topped $301.1 million. The company's NDA filing for golodirsen with priority review and a PDUFA of August 19 is notable. Golodirsen advances Sarepta's RNA strategy. The drug is for patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53.If the company receives approval, it would gain another 8% of the Duchenne community. * 7 A-Rated Stocks That Are Under $10 In the fourth quarter, Sarepta tripled its R&D spending, to $146.2 million. $10.4 million of the costs in clinical and manufacturing expenses also include a ramp up in manufacturing activities for Golodirsen.Sarepta is scheduled to report first-quarter results on May 29, after market close. Incyte Corporation (INCY)Source: Eastern Washington University via Flickr (modified)Incyte Corporation's (NASDAQ:INCY) 14% monthly drop on the stock market, to a recent closing price of $73.52, should pique value investor interest. In the fourth quarter, the company reported revenue growing 25.2% to $468.4 million. Non-GAAP EPS came in at 40 cents.The markets may have a memory that is too short-term. In the quarter, it saw a growth of 22% from Jakafi, 19% from Iclusig and 28% growth in Jakavi royalties. Jakafi is used for the treatment of intermediate or high-risk myelofibrosis. Management forecast Jakafi sales of $1.58 billion to $1.65 billion in 2019. Olumiant is now adding meaningfully to the company's top-line results. The drug is used to treat adults with moderate to severely active rheumatoid arthritis.Incyte forecasts the royalty revenue for both Jakavi and Olumiant growing by around 20%. Overall, sales are expected to grow by between 14% and 19% in 2019.Management is confident that its rich product portfolio will accelerate revenue growth. Already, top-line growth is due to revenue growth exceeding expense growth.Incyte's strong balance sheet, with cash growing to $1.4 billion last year, gives the company the flexibility to develop products. Pursuing Phase 1 products will take a few years to pay off. Investors who are patient and buy and hold INCY stock will get rewarded if these projects are successful. Vertex Pharmaceuticals (VRTX)Source: Shutterstock Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a narrow range of between $180-$190 for most of 2019, only to fall below $168 in recent sessions. Investors may be getting nervous over its valuation, where its forward P/E is 28 times.Vertex grows through investing in transformative medicines that offer a benefit, regardless of modality. It develops drugs for cystic fibrosis while expanding its pipeline. In 2018, it initiated clinical development of CRISPR-Cas9 treatment in Beta -Thalassemia and Sickle cell disease. This year, it aims to advance one or more compounds from research into clinical development.Vertex reported revenue from the CF product line topping $3.04 billion in 2018, up from $2.17 billion in 2017. The company saw a sharp increase in the number of patients being treated by its approved medicines. The launch of Symdeko in the U.S. and multiple label expansions for Kalydeco and Orkambi also added meaningfully to results.In 2019 and beyond, the company forecasts that with a triple combination regimen, it has the potential to increase treatment from ~44,000 to ~68,000 worldwide.Non-GAAP operating income also grew sharply, from $564 million in 2017 to $1.11 billion in 2018. For 2019, Vertex forecasts operating income of $1.35 billion. * 7 Cloud Stocks to Buy Now The 15 analysts who cover VRTX stock have, according to Tipranks, $209 price target, which implies the stock could rise by 23% in the next year. Investors should look at Vertex after the stock's recent drop. Bluebird bio (BLUE)Source: Shutterstock Bluebird bio (NASDAQ:BLUE) fell about 12% in the last week alone, on no company-specific news. Just as markets quickly forgot the strong quarterly earnings report for the other biotech stocks mentioned, investors did the same with BLUE stock.Bluebird expects LentiGlobin in TDT, a gene therapy, to win approval in 2019. But the company said the launch will be country-by-country progressive in Europe. The upside of this approach is that the company will not commit any major hiccups on the launch. The downside is that the revenue growth from sales will be slow. However, this should not concern investors who have a long-term time horizon in mind.Last December 2018, the company presented new data for LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT). It also discussed results for its Phase 1/2 HGB-206 study. And in November 2018, it completed enrollment for its Phase 2 study evaluating the efficacy and safety of bb2121 in patients with relapsed/refractory multiple myeloma.Bluebird ended the fourth quarter with $1.9 billion in cash equivalents and marketable securities. With the most recent cash raise of $600.6 million in July 2018, the company is unlikely to issue any more shares in the short-term. Instead, the company may invest prudently in its clinical studies to advance drug development. Any good news from these studies will drive the stock price back to yearly highs.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 7 A-Rated Stocks That Are Under $10 * 3 Scorching Hot Bank Stocks to Consider Now * 10 Stocks to Sell Before They Give Back 2019 Gains * 7 Stocks to Buy That Ought to Buy Back Shares Compare Brokers The post 5 Biotech Stocks for a Long-Lived Portfolio appeared first on InvestorPlace.

  • TripAdvisor CEO’s compensation plunged 95 percent in 2018
    American City Business Journals27 days ago

    TripAdvisor CEO’s compensation plunged 95 percent in 2018

    After ending 2017 as one of the highest-paid executives in Massachusetts, TripAdvisor CEO Stephen Kaufer's overall pay dropped 95 percent last year, returning to 2016 levels.

  • Sarepta CEO's pay dropped 98 percent in 2018
    American City Business Journals27 days ago

    Sarepta CEO's pay dropped 98 percent in 2018

    In his second year at the helm of one of Boston's few commercial-stage biotech companies, the Sarepta Therapeutics CEO's overall pay dropped close to 98 percent.

  • What's in the Cards for Sarepta (SRPT) This Earnings Season?
    Zacks27 days ago

    What's in the Cards for Sarepta (SRPT) This Earnings Season?

    Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.

  • Benzingalast month

    Jim Cramer Gives His Opinion On Sarepta, Blackstone, Tractor Supply And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said he wouldn't buy Sarepta Therapeutics Inc (NASDAQ: SRPT ) because it's a one-drug company. Cramer wouldn't buy The Blackstone Group L.P. ...

  • Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
    Zackslast month

    Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

    Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 3 Stocks Warren Buffett Would Love
    Motley Foollast month

    3 Stocks Warren Buffett Would Love

    Want to invest like the great value investor? These stocks might appeal to you.

  • Pfizer Stock Suffers From an Underappreciated Drugs Pipeline
    InvestorPlacelast month

    Pfizer Stock Suffers From an Underappreciated Drugs Pipeline

    When Pfizer (NYSE:PFE) won its first approval for cancer drug Ibrance back in February 2015, as a treatment for ER+/HER2- breast cancer, investors were cautiously optimistic. PFE stock holders knew it worked well enough for a narrow subset of breast cancer patients, but expectations for the then-nascent therapy were clearly high.Source: Maciek Lulko (Modified)The drug hasn't disappointed. Since early 2015, Ibrance has been approved for three more indications, with the most recent one taking shape just this month. As it turns out, the treatment has proven effective as a therapy for some of the rare cases where men develop breast cancer.It's a testament to the drug's incredible versatility and efficacy.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd yet, while Ibrance is still in trials looking for even more approved uses, the company's future hardly hinges on what's quickly turning into a blockbuster drug. The market is largely overlooking much of Pfizer's pipeline. Catalysts AheadBank of America Merrill Lynch analyst Jason Gerberry made the point of making the call three weeks ago, upping the brokerage firm's price target on PFE stock from $45 to $48 on upcoming catalysts related to the development of two orphan drugs.Orphan drugs, in short, take aim at underserved areas of the pharmaceutical market. In many cases there are so few cases of a particular illness that no pharmaceutical company bothers developing an option, so when one does, the FDA facilitates an easier path to approval; something is better than nothing.One such drug in Pfizer's pipeline is Vyndaqel.It's not a new drug. In fact, it was first approved back in 2011. Its potential use as a treatment for cardiomyopathy, however, is in the works, and is expected to launch later this year to a receptive caregiver environment.All told, BofA-ML's Gerberry sees peak sales of $2 billion for Vyndaqel.Gerberry also notes that a Pfizer gene therapy candidate -- PF-06939926 for Duchenne muscular dystrophy -- is closer to the endzone than many current and would-be owners of PFE stock may realize. Though in Phase 1 testing right now, should the R&D update slated for the middle of the year go as well as expected, the drugmaker may be able to leap straight to Phase 3 trials and catch up with a similar development from DMD rival Sarepta Therapeutics (NASDAQ:SRPT). * 7 High-Risk Stocks With Big Potential Rewards Again, it's not only another catalyst that could draw a bullish crowd, but it's also a development that could put real revenue growth on the table real soon. The Duchenne muscular dystrophy market could be worth more than $4 billion by 2023.Outside of Gerberry's discussion, Pfizer's Vizimpro was approved earlier this month in Europe as a first-line treatment of locally advanced or metastatic non-small cell lung cancer.Pfizer's still got its R&D, or at least its therapy-acquiring, chops. Heavy HittersThough PF-06939926 and Vyndaqel should prove to be solid bolt-on revenue and profit centers, there's still little doubt that Ibrance will be the company's heavy hitter -- and growth driver -- for the foreseeable future.As of the company's most recent quarterly report, 12-month revenue for the wonder drug reached $4.1 billion, up 32% from the trailing-12-month figure reported a year earlier. New approvals and expanded usage for previously approved indications both helped.The drug, though, has still only scratched the surface. Some analysts are calling for peak revenue of around $8 billion before Ibrance runs out of room to grow and is crimped by rival drugs.Again, that potential is a testament to the drug's flexibility.Ibrance isn't the only heavy-hitter still in growth mode in Pfizer's lineup though. While Enbrel (sold by Pfizer in Europe), Sutent and Celebrex may all be major names with declining revenue, sales of fibromyalgia treatment Lyrica appear to have stabilized around an annual pace of $4.6 billion. Ditto for pneumococcal bacteria treatment Prevnar, which has driven more than $5 billion in sales over the course of the past four reported quarters.In the meantime, Pfizer has started to shine in an area that had quietly gnawed at PFE stock owners… biosimilars. The company has sold $642 million worth of ulcerative colitis, arthritis and plaque psoriasis drug Inflectra/Remsima over the past year, up 50% year-over-year, and suggesting it doesn't have to yield to the pharmaceutical industry's biosimilar powerhouses like Novartis (NYSE:NVS) and Amgen (NASDAQ:AMGN). * 7 Stocks to Buy for Spring Season Growth Pfizer's got five biosimilar drugs in the works, positioning it for deeper penetration of an admittedly-crowded market forecasted to be worth more than a stunning $60 billion by 2024. Bottom Line for PFE StockPFE stock is down 15% from its November peak, never really rebounding with the rest of the market beginning in January. Shares are down 10% just since early April, as the future of U.S. health care has become blurred by political rhetoric. Indeed, Pfizer stock hasn't made net progress since the middle of last year. Clearly there's something wrong with the company.Or, maybe there isn't.Though the headlines and sentiment seem dire, that pessimism is largely rooted in investors' collective view that sees a glass as half-empty rather than half-full. Pfizer's got a quietly potent pipeline, though, with a mix of already-approved and new drugs closer to wrapping up clinical trials than many investors might realize.That may not be enough to stave off headline-driven headwinds in the short run. But, there's a reason a streak of downgrades late last year has been countered this year with a couple of upgrades to an "Outperform'" rating.One of those upgrades came from Credit Suisse, with analyst Vamil Divan noting that patent woes working against aforementioned therapies like Enbrel and Celebrex are starting to abate at the same time new therapies are reaching their full stride.It's just a story not many investors are paying attention to right now.As of this writing, James Brumley did not hold a position in any of the aforementioned companies. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post Pfizer Stock Suffers From an Underappreciated Drugs Pipeline appeared first on InvestorPlace.

  • Here is What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT)
    Insider Monkeylast month

    Here is What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT)

    We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of December 31st. In this article we look at what those investors think of Sarepta Therapeutics Inc (NASDAQ:SRPT). Is Sarepta Therapeutics […]

  • Wave Life Sciences Plunges After DMD Study Data Readout
    Zackslast month

    Wave Life Sciences Plunges After DMD Study Data Readout

    Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.